Canine Atopic Dermatitis: Welfare Outcomes of Biologic Treatments

Atopic dermatitis is a chronic allergic skin condition causing intense pruritis in dogs, with newer biologic treatments offering significantly improved welfare outcomes compared to traditional management.

Key Facts

Canine atopic dermatitis affects approximately 10% of the dog population globally
The condition is driven by immune dysregulation and skin barrier dysfunction
Traditional management with corticosteroids carries significant long-term side effect risks
Oclacitinib (Apoquel) and lokivetmab (Cytopoint) provide rapid and effective pruritis control
Allergen-specific immunotherapy offers potential long-term modification of the allergic response

Welfare Considerations

Canine atopic dermatitis causes chronic intense pruritis, self-trauma, sleep disruption, and the frustration of unrelievable itch — a significant ongoing welfare compromise in affected dogs. Traditional management with corticosteroids causes iatrogenic welfare problems including immune suppression, Cushing-like effects, and skin fragility. Newer biologic treatments including JAK inhibitors and monoclonal antibodies provide rapid, effective pruritis control with fewer systemic side effects, representing a meaningful welfare advancement. Early diagnosis and access to effective management prevents the chronic cycle of itch-scratch-trauma-infection that causes cumulative welfare harm.

What You Can Do

Seek early dermatological assessment for dogs with recurrent skin problems to establish a diagnosis
Discuss biologic treatment options including oclacitinib and lokivetmab with your vet
Consider allergen-specific immunotherapy as a long-term welfare-positive management approach
Monitor welfare outcomes including sleep quality, self-trauma, and activity levels during treatment
Engage your vet in regular review of treatment effectiveness and dose optimisation